Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic...

Keywords

MedicineMinimal clinically important differenceQuality of life (healthcare)GemcitabineClinical endpointInternal medicineConfidence intervalSurgeryPhysical therapyRandomized controlled trialChemotherapy

Affiliated Institutions

Related Publications

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

Elizabeth Poplin , Yang Feng , Jordan Berlin +9 more

Purpose Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clin...

2009 Journal of Clinical Oncology 423 citations

Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)

Mariacristina Di Marco , Roberto Di Cicilia , Marina Macchini +4 more

Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year...

2010 Oncology Reports 124 citations

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

Philip A. Philip , Jacqueline Benedetti , Christopher L. Corless +12 more

Purpose Patients with advanced pancreas cancer present with disease that is poorly responsive to conventional therapies. Preclinical and early clinical evidence has supported ta...

2010 Journal of Clinical Oncology 622 citations

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Volker Heinemann , D. Quietzsch , Frank Gieseler +17 more

Purpose To compare the effectiveness and tolerability of gemcitabine plus cisplatin with single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic p...

2006 Journal of Clinical Oncology 682 citations

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma

Giuseppe Colucci , Francesco Giuliani , Vittorio Gebbia +7 more

Abstract BACKGROUND A prospective, randomized Phase III trial was performed to determine whether, compared with gemcitabine (GEM) alone, the addition of cisplatin (CDDP) to GEM ...

2002 Cancer 280 citations

Publication Info

Year: 2010
Type: article
Volume: 46
Issue: 15
Pages: 2753-2762
Citations: 106
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

106

OpenAlex

Cite This

APA Style

                            
                                
                                    Franck Bonnetain, 
                                
                                    Laëtitia Dahan, 
                                
                                    E. Maillard
                                
                                et al.
                            
                            (2010). 
                            Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. 
                            European Journal of Cancer
                            , 46
                            (15)
                            , 2753-2762.
                            https://doi.org/10.1016/j.ejca.2010.07.023
                        

Identifiers

DOI: 10.1016/j.ejca.2010.07.023